Rheumatoid arthritis (RA) has no single cause. It develops when a combination of genetic susceptibility, hormonal factors, and environmental triggers pushes the immune system to attack the body’s own joint tissue. Understanding these overlapping causes helps explain why some people develop RA and others don’t, even within the same family.
Genetics Set the Stage
Your genes don’t guarantee you’ll get RA, but they heavily influence your odds. The strongest known genetic risk factor is a set of variations in a gene called HLA-DRB1, which helps the immune system distinguish between the body’s own proteins and foreign invaders. About 70% of people with the most common form of RA carry a specific version of this gene known as the “shared epitope.” People who inherit two copies of it face the highest risk.
Family history tells a clearer story than any single gene test. If one of your parents or siblings has RA, your odds of developing it are roughly three times higher than average. If a sibling has it, the risk is about 3.6 times higher. Having two or more first-degree relatives with RA pushes the odds to about seven times the baseline. Even second-degree relatives (aunts, uncles, grandparents) with RA roughly double your risk. These numbers hold up consistently across large population studies.
How the Immune System Turns on Itself
The central event in RA is a process where the immune system begins producing antibodies against the body’s own proteins. In healthy tissue, proteins contain an amino acid called arginine. Under certain conditions, enzymes convert that arginine into a slightly different molecule called citrulline. This small chemical change can make familiar proteins look foreign to the immune system, which then produces antibodies to attack them. These are called anti-citrullinated protein antibodies, or ACPAs, and they’re detectable in the blood years before joint symptoms appear.
Once this immune response starts, it doesn’t stay static. The antibodies progressively mutate and diversify, becoming more effective at targeting a wider range of the body’s own proteins over time. The genetic variants that raise RA risk appear to amplify this process by helping immune cells present citrullinated proteins more aggressively, essentially turning a small initial mistake into a sustained, escalating autoimmune attack.
Why Women Are Hit Harder
Women under 50 develop RA four to five times more often than men the same age. After 60, the gap narrows but women still develop it at twice the rate. The pattern strongly implicates sex hormones, particularly estrogen and progesterone.
RA onset clusters around periods when female hormone levels drop sharply. Disease activity often decreases during pregnancy, when estrogen levels are high, then flares in the months after delivery as hormones plummet. The peak age of onset for women aligns with menopause. These observations point to a protective effect of estrogen at certain concentrations. When that protection withdraws, the immune system becomes more prone to the kind of misdirected inflammation that drives RA.
Smoking and Air Pollutants
Smoking is the most well-established environmental trigger for RA. Current smokers face roughly a 30% higher risk of developing the disease compared to people who have never smoked. The mechanism is direct: inhaled smoke irritates lung tissue and activates the same enzymes that convert arginine to citrulline. This creates a pool of altered proteins in the airways, giving the immune system a starting point for producing the autoantibodies that eventually attack the joints.
Occupational exposure to silica dust carries an even sharper risk. Workers exposed to crystalline silica, common in mining, construction, sandblasting, and even some cleaning products, face about 2.5 times the odds of developing RA. High exposure levels are also linked to more severe disease complications, including lung involvement. Importantly, the silica risk is independent of smoking, meaning the two exposures compound each other.
Infections That Prime the Immune System
Certain infections appear to act as a spark in people who are already genetically primed. Epstein-Barr virus (EBV), the virus behind mononucleosis, is the most studied candidate. People with RA carry roughly ten times the normal viral load of EBV in their blood, and their immune systems are measurably less effective at controlling EBV-infected cells. Part of the problem is molecular mimicry: a protein on the surface of EBV shares the same amino acid sequence found in the shared epitope gene variant that raises RA risk. The immune system, trained to fight the virus, may accidentally target the body’s own tissues that look similar.
Because EBV infects most people worldwide but is never fully eliminated from the body, it creates a persistent source of immune stimulation. In susceptible individuals, the chronic antibody response against EBV may blend into the broader autoimmune response that characterizes RA.
Gum Disease and Gut Bacteria
The bacteria involved in periodontal (gum) disease have a surprisingly direct connection to RA. One species in particular, Porphyromonas gingivalis, is the only known bacterium that can citrullinate proteins on its own. It produces its own version of the enzyme that converts arginine to citrulline, and it works even in environments where the human version of the enzyme wouldn’t function. In laboratory studies, infection with this bacterium significantly increased the production of autoantibodies targeting citrullinated proteins. When researchers used a mutant version of the bacterium that lacked this citrullination ability, the autoantibody spike disappeared, confirming the enzyme as the key mechanism.
The gut microbiome adds another layer. A gut bacterium called Prevotella copri is found at unusually high levels in people with early RA, and its abundance correlates with clinical disease markers. More striking, research published in The Lancet Rheumatology found that Prevotella species are already elevated in people who carry the genetic profile for RA but haven’t developed the disease yet. This suggests the gut microbiome shifts early, potentially years before symptoms, and that genetic makeup itself may shape which bacteria thrive in the gut.
Obesity and Chronic Inflammation
Excess body fat isn’t just stored energy. Fat tissue actively secretes signaling molecules called adipokines that regulate inflammation throughout the body. In obesity, this system tilts heavily toward pro-inflammatory output. Fat cells release a cascade of inflammatory signals, including molecules that promote joint tissue breakdown and stimulate the immune cells involved in RA.
One adipokine, leptin, plays a particularly notable role. It stimulates the migration of cells that line the joints and promotes the growth of new blood vessels in inflamed tissue, both hallmarks of RA progression. It also triggers cartilage cells to release enzymes that break down the joint surface. Another, called visfatin, is produced in large quantities by deep abdominal fat and ramps up the production of multiple inflammatory molecules. Animal studies have shown that mice lacking fat tissue entirely are resistant to induced arthritis, and that a fat-specific protein called adipsin is essential for arthritis to develop. These findings establish body fat as an active participant in joint inflammation, not merely a bystander.
How These Causes Work Together
RA rarely results from any single factor acting alone. The current model involves a multi-step process that can unfold over years. First, genetic susceptibility sets a baseline level of risk, primarily through immune system genes that influence how the body handles altered proteins. Second, environmental exposures like smoking, silica dust, infections, or gum disease generate citrullinated proteins and provoke an initial immune response. Third, hormonal shifts, obesity, or gut microbiome changes create a sustained inflammatory environment that allows that immune response to escalate rather than resolve.
Autoantibodies often appear in the blood five to ten years before the first joint symptoms. During this preclinical window, the immune response is quietly expanding, diversifying, and becoming more aggressive. By the time joint pain, swelling, and stiffness arrive, the autoimmune process is already well established. This is why researchers increasingly focus on the preclinical phase, since the causes of RA are really the causes of a slow-building immune cascade, not a sudden event.